NO20032215L - Laktamforbindelse - Google Patents

Laktamforbindelse

Info

Publication number
NO20032215L
NO20032215L NO20032215A NO20032215A NO20032215L NO 20032215 L NO20032215 L NO 20032215L NO 20032215 A NO20032215 A NO 20032215A NO 20032215 A NO20032215 A NO 20032215A NO 20032215 L NO20032215 L NO 20032215L
Authority
NO
Norway
Prior art keywords
lactam compound
lactam
compound
Prior art date
Application number
NO20032215A
Other languages
English (en)
Other versions
NO325217B1 (no
NO20032215D0 (no
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20032215D0 publication Critical patent/NO20032215D0/no
Publication of NO20032215L publication Critical patent/NO20032215L/no
Publication of NO325217B1 publication Critical patent/NO325217B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20032215A 2000-11-17 2003-05-15 Laktamforbindelse, fremgangsmate for dets fremstilling samt farmasoytisk sammensetning inneholdende nevnte forbindelse NO325217B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (3)

Publication Number Publication Date
NO20032215D0 NO20032215D0 (no) 2003-05-15
NO20032215L true NO20032215L (no) 2003-07-16
NO325217B1 NO325217B1 (no) 2008-02-25

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032215A NO325217B1 (no) 2000-11-17 2003-05-15 Laktamforbindelse, fremgangsmate for dets fremstilling samt farmasoytisk sammensetning inneholdende nevnte forbindelse

Country Status (33)

Country Link
US (1) US20040248878A1 (no)
EP (1) EP1353910B1 (no)
JP (1) JP4116431B2 (no)
KR (1) KR20030045194A (no)
CN (2) CN100516047C (no)
AR (1) AR031356A1 (no)
AT (1) ATE362919T1 (no)
AU (2) AU2002224321B2 (no)
BR (1) BR0115424A (no)
CA (1) CA2425497C (no)
CY (1) CY1106682T1 (no)
CZ (1) CZ20031340A3 (no)
DE (1) DE60128587T2 (no)
DK (1) DK1353910T3 (no)
DZ (1) DZ3454A1 (no)
EA (1) EA006919B1 (no)
EC (1) ECSP034598A (no)
ES (1) ES2286162T3 (no)
HR (1) HRP20030385A2 (no)
HU (1) HUP0301862A3 (no)
IL (1) IL155275A0 (no)
MX (1) MXPA03004250A (no)
MY (1) MY141607A (no)
NO (1) NO325217B1 (no)
PE (1) PE20020798A1 (no)
PL (1) PL211018B1 (no)
PT (1) PT1353910E (no)
SK (1) SK287794B6 (no)
SV (1) SV2003000741A (no)
TW (1) TWI235151B (no)
UA (1) UA77165C2 (no)
WO (1) WO2002040451A2 (no)
ZA (1) ZA200303411B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
PT1572215E (pt) 2002-12-20 2009-12-09 Glaxo Group Ltd Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2603320A1 (en) 2005-04-08 2006-10-19 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
EP1985615A4 (en) 2006-01-31 2011-12-14 Api Corp PROCESS FOR THE PREPARATION OF BENZAZEPINONE
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP2987496B1 (en) 2013-04-19 2018-08-08 National University Corporation Okayama University Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
WO2021195362A1 (en) 2020-03-26 2021-09-30 Seagen Inc. Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU1569501A (en) * 1999-11-09 2001-06-06 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
MY141607A (en) 2010-05-31
MXPA03004250A (es) 2003-09-22
AR031356A1 (es) 2003-09-17
ECSP034598A (es) 2003-06-25
KR20030045194A (ko) 2003-06-09
DZ3454A1 (fr) 2002-05-23
HUP0301862A3 (en) 2007-09-28
AU2432102A (en) 2002-05-27
CN100516047C (zh) 2009-07-22
JP4116431B2 (ja) 2008-07-09
SK5432003A3 (en) 2004-09-08
UA77165C2 (en) 2006-11-15
ES2286162T3 (es) 2007-12-01
CA2425497C (en) 2010-08-17
EA200300579A1 (ru) 2003-12-25
CN1575282A (zh) 2005-02-02
WO2002040451A2 (en) 2002-05-23
EP1353910B1 (en) 2007-05-23
US20040248878A1 (en) 2004-12-09
NO325217B1 (no) 2008-02-25
CY1106682T1 (el) 2012-05-23
EP1353910A2 (en) 2003-10-22
AU2002224321B2 (en) 2006-10-19
NO20032215D0 (no) 2003-05-15
PT1353910E (pt) 2007-08-20
PL360991A1 (en) 2004-09-20
DK1353910T3 (da) 2007-09-10
ATE362919T1 (de) 2007-06-15
DE60128587D1 (de) 2007-07-05
CZ20031340A3 (cs) 2004-06-16
HRP20030385A2 (en) 2003-08-31
WO2002040451A3 (en) 2003-08-28
SV2003000741A (es) 2003-01-13
SK287794B6 (sk) 2011-10-04
CA2425497A1 (en) 2002-05-23
BR0115424A (pt) 2003-10-21
ZA200303411B (en) 2004-08-02
TWI235151B (en) 2005-07-01
PL211018B1 (pl) 2012-03-30
IL155275A0 (en) 2003-11-23
JP2004521084A (ja) 2004-07-15
DE60128587T2 (de) 2008-01-31
PE20020798A1 (es) 2002-09-06
EA006919B1 (ru) 2006-04-28
HUP0301862A2 (hu) 2003-09-29
CN101624372A (zh) 2010-01-13

Similar Documents

Publication Publication Date Title
NO20032236D0 (no) Laktamforbindelse
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
ATE307121T1 (de) Substituierte arylpyrazine
AR028393A1 (es) Iminoazidas substituidas
NO20032215D0 (no) Laktamforbindelse
PT1268453E (pt) Metabolitos de agonista/antagonista de estrogenio
ID29755A (id) Senyawa-senyawa organosilikon
ATE365721T1 (de) Substituierte benzoylcyclohexenone
AR028302A1 (es) Feniluracilos substituidos
IT250181Y1 (it) Custodia perfezionata per rivoltella
ATE372338T1 (de) Deshalogenverbindungen
NO20030303L (no) Kalsilytiske forbindelser
NO20023508D0 (no) Kalsilyttiske forbindelser
NO20031837D0 (no) Kalsilytiske forbindelser
TR200100070A3 (tr) Bilesim
MX231963B (es) Poliamidas
ATA19392000A (de) Kippflügelflugzeug
SE0003477D0 (sv) Compounds
SE0004680D0 (sv) New compound
SE0003436D0 (sv) Novel compounds
SE0003437D0 (sv) Novel compounds
SE0002331D0 (sv) Novel compounds
SE0003641D0 (sv) Novel compounds